For the study, published Sept. 25 in Journal of the American Medical Informatics Association, researchers conducted an analysis of 264 patients evaluated for abnormal pulse detected using Apple Watch over a four-month period.
Of the study participants, clinical documentation for 15.5 percent noted an abnormal pulse alert, while preexisting AFib was noted in 22 percent. The patients received testing including echocardiography, Holter monitor and chest X-rays to check their cardiovascular health.
After performing the diagnostic tests, only 11.4 percent of patients were clinically diagnosed with a cardiovascular condition. Of the 41 patients who received an explicit alert from Apple Watch detecting an irregular pulse, only six individuals (15 percent) were clinically diagnosed.
Researchers concluded that the FDA and Apple should consider the unintended consequences of direct-to-consumer AFib screening, including false positive screening results.
More articles on consumerism:
How CRM technologies drive a connected patient experience: 5 insights
Nearly half of iPhone users own a connected health device
How to navigate the shift to a digital-first engagement strategy: 3 Qs with Salesforce’s Dr. Sindhu Pandit and Wendy Cofran
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
